{
  "meta": {
    "title": "11_Heart_Failure_Drugs",
    "url": "https://brainandscalpel.vercel.app/11-heart-failure-drugs-1f73452b.html",
    "scrapedAt": "2025-11-30T12:34:06.266Z"
  },
  "questions": [
    {
      "text": "What is the half-life of digoxin?",
      "choices": [
        {
          "id": 1,
          "text": "24 hrs"
        },
        {
          "id": 2,
          "text": "40 hrs"
        },
        {
          "id": 3,
          "text": "72 hrs"
        },
        {
          "id": 4,
          "text": "60 hrs"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The plasma <strong>half-life of digoxin</strong> is around <strong>40 hours</strong> (36-40 hours).</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>Digitoxin&nbsp;</td>\n<td>Digoxin&nbsp;</td>\n</tr>\n<tr>\n<td>Oral absorption&nbsp;</td>\n<td>Very good (90-100%)&nbsp;</td>\n<td>Good (60-80%)&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>Plasma protein binding&nbsp;&nbsp;</td>\n<td>95%(t<sub>1/2</sub>&nbsp;5-7 days)&nbsp;</td>\n<td>25%(t<sub>1/2</sub>&nbsp;40 hrs)&nbsp;</td>\n</tr>\n<tr>\n<td>Elimination&nbsp;</td>\n<td>Hepatic metabolism&nbsp;</td>\n<td>Renal excretion (by glomerular filtration)&nbsp;</td>\n</tr>\n<tr>\n<td>Dose adjustment in&nbsp;</td>\n<td>Liver failure&nbsp;</td>\n<td>Kidney failure&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p class=\"ng-binding\">Therapeutic levels of digoxin in the range of 0.5-0.8 ng/ml are beneficial.&nbsp;An increase in levels &gt;1.2 ng/mL is associated with increased mortality.</p>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4740",
      "difficulty": "medium"
    },
    {
      "text": "Digitalis inhibits Na+/ K+ ATPase pump in cardiac muscle cell membrane. How does this lead to its positive inotropic effect?",
      "choices": [
        {
          "id": 1,
          "text": "By decreasing activity of Na+/Ca++ exchanger causing decreased influx of sodium and decreased efflux of Ca++"
        },
        {
          "id": 2,
          "text": "By decreasing efflux of Na+ leading to less negative resting membrane potential and opening of voltage gated Ca++ channels on the T tubules"
        },
        {
          "id": 3,
          "text": "By increasing intracellular Na+ causing increased efflux of Na+ and increased influx of Ca++ through Na+/Ca++ exchanger"
        },
        {
          "id": 4,
          "text": "By increasing intracellular Na+ decreasing the activity of Ca++ pump in the sarcoplasmic reticulum"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The positive ionotropic effect of digitalis is due to <strong>decreased</strong> activity of <strong>Na<sup>+</sup>/Ca<sup>2+</sup> exchanger</strong> causing a decreased influx of sodium and decreased efflux of Ca<sup>2+</sup>.</p>\n<p>Digitalis selectively binds&nbsp;and<strong> inhibits</strong>&nbsp;the<strong>&nbsp;Na<sup>+</sup>/ K<sup>+</sup>ATPase pump </strong>of myocardial fibers which<strong>&nbsp;</strong>normally pushes Na<sup>+</sup> outside and brings K<sup>+</sup> inside. When this pump is inhibited, there is an <strong>intracellular accumulation of Na<sup>+</sup></strong> ions. This results in a relative <strong>decrease </strong>in the <strong>expulsion of Ca<sup>2+</sup></strong> ions via the Na<sup>+</sup>-Ca<sup>2+</sup> exchanger (NCX) leading to the&nbsp;accumulation of calcium inside the cells resulting in <strong>increased contractility.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/32226b02e4fb4015ac8795d22c1a6cf6x1280x1527.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4714",
      "difficulty": "medium"
    },
    {
      "text": "The action of digoxin will not be affected in which of the following patients?",
      "choices": [
        {
          "id": 1,
          "text": "43-year-old man with chronic liver disease"
        },
        {
          "id": 2,
          "text": "30-year-old woman with electrolyte disturbances"
        },
        {
          "id": 3,
          "text": "82-year-old man with renal failure"
        },
        {
          "id": 4,
          "text": "60-year-old woman with myocardial infarction"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The action of digoxin is not affected in chronic liver disease.&nbsp;</p>\n<p>Option B:&nbsp;<strong>Electrolyte disturbances</strong> like hypokalemia, hypomagnesemia, and hypercalcemia&nbsp;<strong>increase digitalis toxicity.</strong></p>\n<p>Option C: Digoxin is<strong>&nbsp;excreted </strong>unchanged primarily by<strong> kidneys</strong>&nbsp;by glomerular filtration. Therefore, <strong>dose adjustment</strong> of digoxin has to be done in&nbsp;<strong>renal failure</strong>.</p>\n<p>Option D: Chances of arrhythmias increases manifold in post-MI duration. Hence, it is generally avoided post-MI as <strong>digitalis</strong> itself <strong>causes arrhythmias</strong>.</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Digitoxin&nbsp;</strong></td>\n<td><strong>Digoxin&nbsp;</strong></td>\n</tr>\n<tr>\n<td>Oral absorption&nbsp;</td>\n<td>Very good (90-100%)&nbsp;</td>\n<td>Good ( 60-80%)&nbsp;i/v also&nbsp;</td>\n</tr>\n<tr>\n<td>Plasma protein binding&nbsp;&nbsp;</td>\n<td>95%&nbsp;</td>\n<td>25%&nbsp;</td>\n</tr>\n<tr>\n<td>Elimination&nbsp;</td>\n<td>Hepatic metabolism&nbsp;</td>\n<td>Renal excretion (by glomerular filtration)&nbsp;</td>\n</tr>\n<tr>\n<td>Dose adjustment in&nbsp;</td>\n<td>Liver failure&nbsp;</td>\n<td>Kidney failure&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4735",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following does not increase the risk of digoxin toxicity?",
      "choices": [
        {
          "id": 1,
          "text": "Renal impairment"
        },
        {
          "id": 2,
          "text": "Hyperkalemia"
        },
        {
          "id": 3,
          "text": "Hypercalcemia"
        },
        {
          "id": 4,
          "text": "Hypomagnesemia"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Digoxin toxicity is not increased by hyperkalemia.</p>\n<p>In hyperkalemia, the ATPase alpha subunit is <strong>dephosphorylated</strong>, which is the binding site of digoxin. This <strong>reduces</strong> it's <strong>binding</strong> and effect. Therefore, hyperkalemia does not increase digoxin toxicity.</p>\n<p>Factors predisposing digoxin toxicity<strong>:</strong> </p>\n<ul>\n<li>Hypokalemia (more digoxin binds to the Na<sup>+</sup>/K<sup>+</sup> ATPase)</li>\n<li>Hypercalcemia (increases the risk of arrhythmia)</li>\n<li>Hypomagnesemia<strong> </strong>(Mg<sup>++</sup> is a co-factor for Na<sup>+</sup>/K<sup>+</sup> ATPase)</li>\n<li>Renal failure (for digoxin)</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4715",
      "difficulty": "easy"
    },
    {
      "text": "A patient is to be started on digoxin therapy for heart failure. Despite already being on another drug, dose adjustment of digoxin is not necessary for this patient. Identify this drug.",
      "choices": [
        {
          "id": 1,
          "text": "Amiodarone"
        },
        {
          "id": 2,
          "text": "Quinidine"
        },
        {
          "id": 3,
          "text": "Captopril"
        },
        {
          "id": 4,
          "text": "Levosimendan"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Levosimendan</strong> does not increase digitalis toxicity and hence would not require dose adjustment of digoxin.</p>\n<p>It is a combined Ca2+ channel sensitizer (troponin C binding) and PDE3 inhibitor.&nbsp;</p>\n<p><strong>Digoxin</strong> is <strong>metabolized</strong> by <strong>P-glycoprotein&nbsp;</strong>and drugs that inhibit it increase the plasma levels of digoxin and may result in toxicity. The drugs that increase digoxin toxicity are:</p>\n<ul>\n<li>Amiodarone</li>\n<li>Quinidine</li>\n<li>Propafenone</li>\n<li>Verapamil</li>\n<li>Captopril</li>\n<li>Erythromycin</li>\n<li>Gentamycin</li>\n<li>Ranolazine</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4724",
      "difficulty": "medium"
    },
    {
      "text": "What is the most appropriate treatment for a patient with severe digoxin toxicity?",
      "choices": [
        {
          "id": 1,
          "text": "Potassium supplements"
        },
        {
          "id": 2,
          "text": "Propafenone"
        },
        {
          "id": 3,
          "text": "Quinidine"
        },
        {
          "id": 4,
          "text": "Fab fragments of digoxin antibodies"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The most appropriate treatment for severe digoxin toxicity is<strong> purified Fab fragments of digitalis antibodies </strong>(Digibind).</p>\n<p>It <strong>neutralizes the digoxin action</strong> and its dosage is based upon the total dose of digoxin ingested.</p>\n<p>Option A: <strong>KCl infusion</strong> is indicated in <strong>mild toxicity</strong> as hyperkalemia decreases the binding of digoxin by dephosphorylating Na/K ATPase pump. In acute severe poisoning, potassium is not indicated as it may already be high in plasma. Potassium is also not indicated when a higher degree of AV block is present.</p>\n<p>Options B and C: Quinidine and propafenone are not indicated in arrhythmias caused by digoxin.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4741",
      "difficulty": "easy"
    },
    {
      "text": "An ECG is done for a patient suspected to have digoxin toxicity. Which of the following would you not expect to see on the ECG?",
      "choices": [
        {
          "id": 1,
          "text": "Ventricular bigeminy"
        },
        {
          "id": 2,
          "text": "Paroxysmal atrial tachycardia with fast ventricular rate"
        },
        {
          "id": 3,
          "text": "Regularisation of atrial fibrillation"
        },
        {
          "id": 4,
          "text": "Bidirectional ventricular tachycardia"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Digoxin&nbsp;</strong>can cause either paroxysmal or non-paroxysmal<strong> atrial tachycardia with variable A-V block </strong>but not a fast ventricular rate.</p>\n<p><strong>Regularisation of atrial fibrillation</strong> with complete A-V block and junctional or ventricular escape rhythm can occur because of the blockade of A-V conduction. Due to the <strong>blockade of AV node by digoxin</strong>, it is contraindicated in WPW syndrome.</p>\n<p>Common arrhythmias associated with digoxin toxicity:</p>\n<ul>\n<li><strong>Ventricular bigeminy</strong></li>\n<li>Atrioventricular junctional rhythm</li>\n<li><strong>Bidirectional ventricular tachycardia</strong></li>\n<li>Premature ventricular depolarizations.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4731",
      "difficulty": "medium"
    },
    {
      "text": "A patient with heart disease presents to the emergency with severe vomiting and blurry vision and mentions that he sees a greenish-yellow tinge over all objects. He then develops ventricular arrhythmia. What would be the most appropriate drug for immediate management?",
      "choices": [
        {
          "id": 1,
          "text": "Procainamide"
        },
        {
          "id": 2,
          "text": "Lignocaine"
        },
        {
          "id": 3,
          "text": "Atropine"
        },
        {
          "id": 4,
          "text": "Propranolol"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario is suggestive of <strong>digoxin toxicity. Xanthopsia </strong>i.e.,<strong>&nbsp;</strong>yellowing of vision is characteristically seen in this condition.&nbsp;<strong>Lignocaine </strong>(and&nbsp;phenytoin) has the least effect on AV nodal conduction&nbsp;and is the&nbsp;most appropriate&nbsp;drug for the <strong>treatment</strong> of&nbsp;<strong>digoxin-induced arrhythmias.</strong></p>\n<p>Option A: <strong>Procainamide</strong> and other class IA anti-arrhythmic agents are <strong>not indicated</strong> in digoxin toxicity because of their inhibitory effects on AV nodal conduction.</p>\n<p>Option C: <strong>Atropine</strong> is used for <strong>atrial bradyarrhythmias</strong> associated with digoxin toxicity.</p>\n<p>Option D: <strong>Propranolol</strong> is used for <strong>atrial tachyarrhythmias</strong> associated with digoxin toxicity.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4742",
      "difficulty": "easy"
    },
    {
      "text": "A patient is diagnosed with congestive heart failure. Which of the following is not prescribed to prevent progression and revert cardiac remodelling?",
      "choices": [
        {
          "id": 1,
          "text": "Beta blocker"
        },
        {
          "id": 2,
          "text": "ACE inhibitor"
        },
        {
          "id": 3,
          "text": "Digoxin"
        },
        {
          "id": 4,
          "text": "Aldosterone antagonist"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Digoxin</strong> has no role in preventing cardiac remodelling. It increases cardiac contractility and is indicated for <strong>symptomatic management</strong> of congestive heart failure.</p>\n<p>Drugs preventing ventricular remodelling:</p>\n<ul>\n<li>ACE inhibitors/ ARBS</li>\n<li>Beta-blockers</li>\n<li>Aldosterone antagonists (spironolactone, eplerenone)</li>\n</ul>\n<p>The activation of RAAS and the sympathetic nervous system leads to the remodelling and progressive LV dysfunction. The RAAS activation is prevented by the ACE inhibitors/ARBs and the aldosterone antagonists (spironolactone), while the overactive sympathetic system is inhibited by the beta-blockers.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7e588cc951734db299c6dc05ac5ec75bx1280x1301.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4793",
      "difficulty": "easy"
    },
    {
      "text": "You are starting a treatment regimen containing an angiotensin-converting enzyme inhibitor for a patient with congestive heart failure.  Which of the following is true regarding its role in the regimen?",
      "choices": [
        {
          "id": 1,
          "text": "It is the drug of choice unless contraindicated"
        },
        {
          "id": 2,
          "text": "Used as an alternative to diuretics"
        },
        {
          "id": 3,
          "text": "It is a substitute for digitalis"
        },
        {
          "id": 4,
          "text": "Used as adjuncts only in resistant cases"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>ACE inhibitors </strong>and<strong> ARBs </strong>are<strong>&nbsp;</strong>the<strong> first choice</strong>&nbsp;drugs in congestive heart failure (CHF) unless contraindicated.</p>\n<p>Renin-angiotensin-aldosterone system (RAAS) activation is pivotal in the development of the symptoms and disease progression in CHF.</p>\n<p>ACE inhibitors and ARBs afford symptomatic as well as disease-modifying benefits in CHF by causing vasodilation, retarding/preventing ventricular hypertrophy, myocardial cell apoptosis and fibrosis.</p><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4757",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following drugs can overcome an increase in heart rate and renin release seen in patients with CHF?",
      "choices": [
        {
          "id": 1,
          "text": "Minoxidil"
        },
        {
          "id": 2,
          "text": "Metoprolol"
        },
        {
          "id": 3,
          "text": "Metolazone"
        },
        {
          "id": 4,
          "text": "Milrinone"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Metoprolol</strong> is a <strong>selective &beta;1</strong>&nbsp;<strong>blocker.</strong> Beta blockade reduces the sympathetic stimulation of the SA node and thus <strong>reduces</strong> the <strong>heart rate</strong>. In the same way, &beta;<sub>1</sub> receptors in the <strong>JG apparatus</strong> are also inhibited by metoprolol, and thus, <strong>renin release</strong> is <strong>reduced</strong>.</p>\n<p>Option A: Minoxidil is a K<sup>+</sup> channel opener that was earlier used in hypertensive emergencies for its vasodilatory action on blood vessels. This has no effect on renin release and heart rate can increase due to reflex sympathetic stimulation.</p>\n<p>Option C: Metolazone is a thiazide diuretic that can be used even in severe renal failure.</p>\n<p>Option D: Milrinone is an inodilator<strong>.</strong> It increases cardiac contractility and causes vasodilation by inhibiting the enzyme PDE3.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4798",
      "difficulty": "medium"
    },
    {
      "text": "You see the cardiologist prescribe a non-selective beta-blocker for a patient with congestive heart failure. He mentions that the drug has several beneficial effects. Identify the drug.",
      "choices": [
        {
          "id": 1,
          "text": "Propranolol"
        },
        {
          "id": 2,
          "text": "Pindolol"
        },
        {
          "id": 3,
          "text": "Metoprolol"
        },
        {
          "id": 4,
          "text": "Carvedilol"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The drug most likely being discussed is <strong>carvedilol</strong>&nbsp;which is a<strong> non-selective beta-blocker </strong>approved for use in<strong>&nbsp;mild to severe CHF</strong>.</p>\n<p>Additional actions of carvedilol:</p>\n<ul>\n<li>Blockade of alpha receptors</li>\n<li>Blockade of L-type calcium channels&nbsp;</li>\n<li>Antioxidant effect</li>\n<li>Antiproliferative effect</li>\n</ul>\n<p>Options A and B:<strong>&nbsp;Propranolol and pindolol</strong> are non-selective beta-blockers but they are&nbsp;<strong>not approved</strong> for use in CHF.</p>\n<p>Option C:&nbsp;<strong>Metoprolol</strong> is approved for use in CHF but it is a <strong>cardioselective</strong> beta-blocker.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4765",
      "difficulty": "medium"
    },
    {
      "text": "β blocker therapy is to be started on a patient with congestive heart failure. Which of the following statements is false about the therapy?",
      "choices": [
        {
          "id": 1,
          "text": "The drugs should be started at optimum doses"
        },
        {
          "id": 2,
          "text": "The dose should be gradually increased over weeks"
        },
        {
          "id": 3,
          "text": "Special precautions should be taken in cases of NYHA class III and IV"
        },
        {
          "id": 4,
          "text": "Carvedilol and metoprolol are the preferred drugs"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Beta-blockers are not started with optimum doses in patients with heart failure.</p>\n<p><strong>Beta-blocker</strong> therapy in <strong>CHF</strong> requires <strong>caution,</strong> proper patient selection, and observance of several guidelines such as:</p>\n<ul>\n<li>Generally,&nbsp;the starting dose is less than 1/8th (low dose) of the target dose is and then <strong>titrated upwards slowly over weeks</strong>&nbsp;(doubling every 4 weeks)</li>\n<li>The greatest utility of beta-blocker therapy has been seen in mild to moderate CHF (NYHA I, II)</li>\n<li>There is no place for beta-blockers in decompensated heart disease</li>\n<li><strong>Carvedilol</strong>, bisoprolol, and <strong>metoprolol</strong> are commonly used beta-blockers in CHF.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4774",
      "difficulty": "medium"
    },
    {
      "text": "You are going through the treatment chart of a patient with chronic congestive heart failure. Which of the following drugs will you not expect to see?",
      "choices": [
        {
          "id": 1,
          "text": "Ivabradine"
        },
        {
          "id": 2,
          "text": "Digoxin"
        },
        {
          "id": 3,
          "text": "Spironolactone"
        },
        {
          "id": 4,
          "text": "Adrenaline"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Adrenaline </strong>is&nbsp;used for the treatment of<strong> acute decompensated heart failure</strong>, not&nbsp;chronic congestive heart failure.<strong>&nbsp;</strong></p>\n<p>Drugs used in chronic congestive heart failure include :</p>\n<ul>\n<li>Diuretics</li>\n<li>ACE inhibitors</li>\n<li>Angiotensin receptor blockers</li>\n<li>Angiotensin receptor-neprilysin inhibitor - sacubitril-valsartan</li>\n<li>Hydralazine</li>\n<li>Nitrates</li>\n<li><strong>Digoxin&nbsp;</strong></li>\n<li><strong>Mineralocorticoid receptor antagonists&nbsp;</strong></li>\n<li><strong>Ivabradine </strong>- sinus node inhibitor&nbsp;</li>\n</ul><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4727",
      "difficulty": "easy"
    },
    {
      "text": "A 70-year-old man is brought with complaints of severe chest pain. The ECG shows anterolateral wall MI and echocardiography shows an ejection fraction of 38%. Which of the following is the drug of choice for his condition?",
      "choices": [
        {
          "id": 1,
          "text": "Dopamine"
        },
        {
          "id": 2,
          "text": "Dobutamine"
        },
        {
          "id": 3,
          "text": "Epinephrine"
        },
        {
          "id": 4,
          "text": "Norpepinephrine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario is suggestive of<strong> acute congestive heart failure with systolic dysfunction. Dobutamine </strong>is administered as it<strong>&nbsp;</strong>is the<strong> beta-adrenergic agonist of choice </strong>for managing this condition.<strong>&nbsp;</strong></p>\n<p>Dobutamine has a well-balanced action with stimulation of cardiac output. It causes less tachycardia than epinephrine and also has an added advantage of a decrease in pulmonary artery wedge pressure.&nbsp;</p>\n<p>At doses that result in a positive inotropic effect, the beta-1 action on the myocardium predominates. In the vasculature, the alpha-1 effects are counterbalanced by beta-2 effects.&nbsp;The <strong>net result</strong> is an <strong>increase</strong> in <strong>stroke volume</strong>, augmented by a small decrease in systemic vascular resistance, thereby resulting in a <strong>decrease in afterload</strong>.</p><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Sotagliflozin, a novel agent that inhibits SGLT 1 as well as SGLT2. It is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure in adults with heart failure, type 2 diabetes mellitus, chronic kidney disease &amp; other cardiovascular risk factors. &quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\"><strong>Sotagliflozin</strong>&nbsp;is a novel agent that inhibits SGLT 1 as well as SGLT2. It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, type 2 diabetes mellitus, chronic kidney disease &amp; other cardiovascular risk factors. </span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2755",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is false about nesiritide?",
      "choices": [
        {
          "id": 1,
          "text": "It is a BNP analogue"
        },
        {
          "id": 2,
          "text": "It can be used in decompensated CHF"
        },
        {
          "id": 3,
          "text": "It can be administered orally"
        },
        {
          "id": 4,
          "text": "It causes loss of Na+ in the urine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Nesiritide</strong> is available for <strong>intravenous administration only </strong>as it is a peptide and is digested by peptidases in the GIT.&nbsp;</p>\n<p>Nesiritide is a<strong> recombinant brain natriuretic peptide (BNP).</strong> It causes <strong>natriuresis</strong> and&nbsp;<strong>vasodilation</strong>. It has a half life of 18 minutes. It is approved to relieve dyspnoea and other symptoms in <strong>acute refractory decompensated CHF.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4786",
      "difficulty": "easy"
    },
    {
      "text": "Which enzyme degrades BNP?",
      "choices": [
        {
          "id": 1,
          "text": "Neutral endopeptidase"
        },
        {
          "id": 2,
          "text": "Elastase"
        },
        {
          "id": 3,
          "text": "Pseudocholinesterase"
        },
        {
          "id": 4,
          "text": "Carboxypeptidase"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Brain natriuretic peptide </strong>(BNP) is degraded by<strong> neutral endopeptidase.</strong></p>\n<p>Natriuretic peptides:</p>\n<ul>\n<li>Atrial natriuretic peptide (ANP)</li>\n<li>Brain natriuretic peptide</li>\n<li>C-type natriuretic peptide</li>\n</ul>\n<p><strong>Nesiritide</strong> is a&nbsp;recombinant BNP<strong>&nbsp;</strong>approved to relieve dyspnoea and other symptoms in&nbsp;<strong>acute refractory decompensated CHF.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4788",
      "difficulty": "easy"
    },
    {
      "text": "Isosorbide dinitrate is indicated for congestive heart failure in combination with which of the following vasodilators?",
      "choices": [
        {
          "id": 1,
          "text": "Minoxidil"
        },
        {
          "id": 2,
          "text": "Hydralazine"
        },
        {
          "id": 3,
          "text": "Nimodipine"
        },
        {
          "id": 4,
          "text": "Nitrendipine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Isosorbide dinitrate </strong>(ISDN) is indicated in combination <strong>with hydralazine for CHF.&nbsp;</strong></p>\n<p><strong>Hydralazine</strong> is a <strong>direct vasodilator</strong> and its mechanism of action is not known. It also reduces nitrate tolerance.</p>\n<p>The combination of ISDN and hydralazine showed mortality benefits in a specific group of population (African-Americans).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2775",
      "difficulty": "medium"
    },
    {
      "text": "A patient with congestive heart failure develops hyponatremia. Which oral vasopressin receptor antagonist will you prescribe for him?",
      "choices": [
        {
          "id": 1,
          "text": "Tolvaptan"
        },
        {
          "id": 2,
          "text": "Conivaptan"
        },
        {
          "id": 3,
          "text": "Both a and b"
        },
        {
          "id": 4,
          "text": "Sacubitril"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Tolvaptan</strong> is an<strong> oral vasopressin receptor antagonist. </strong></p>\n<p>It&nbsp;preferentially binds to V2 receptors over V1a receptors. It has been used in decompensated CHF patients to restore normal sodium levels.</p>\n<p><strong>Conivaptan</strong> is also a vasopressin receptor antagonist that is administered <strong>intravenously</strong> and binds to both V2 and V1a receptors with similar affinity. It is more commonly used for hyponatremia rather than CHF. Oral conivaptan is not yet available.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4795",
      "difficulty": "hard"
    },
    {
      "text": "What is the mechanism of action of milrinone?",
      "choices": [
        {
          "id": 1,
          "text": "Stimulation of PDE3"
        },
        {
          "id": 2,
          "text": "Inhibition of PDE3"
        },
        {
          "id": 3,
          "text": "Inhibition of PDE5"
        },
        {
          "id": 4,
          "text": "Stimulation of PDE5"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Milrinone</strong> acts by<strong> inhibition </strong>of the enzyme phosphodiesterase-3 (<strong>PDE 3</strong>).</p>\n<p>The PDE-3 inhibitors decrease cellular cAMP degradation, resulting in <strong>increased</strong> levels of <strong>cAMP</strong>. This results in positive ionotropic and chronotropic action of the heart. It also dilates veins and arteries thereby decreasing the preload and afterload.</p><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4796",
      "difficulty": "easy"
    },
    {
      "text": "A trial is being conducted to determine the efficacy of a myofilament calcium sensitizer in patients with heart failure. Which among the following is the drug likely being studied?",
      "choices": [
        {
          "id": 1,
          "text": "Levosimendan"
        },
        {
          "id": 2,
          "text": "Omapatrilat"
        },
        {
          "id": 3,
          "text": "Sacubitril"
        },
        {
          "id": 4,
          "text": "Enoximone"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Levosimendan </strong>is a myofilament <strong>calcium senstizer.&nbsp;</strong></p>\n<p>Calcium sensitizers&nbsp;bind and induce a conformational change in thin-filament regulatory protein troponin C. Thus increasing the sensitivity of contractile myofilaments to calcium. The result is an <strong>increased force of contraction</strong> for a given cytosolic calcium concentration.&nbsp;</p>\n<p>Option B: <strong>Omapatrilat</strong> is a <strong>dual ACE </strong>and<strong> neprilysin inhibitor</strong> that failed clinical trials due to increased risk of angioedema.&nbsp;</p>\n<p>Option C: <strong>Sacubitril</strong> is a <strong>neprilysin inhibitor</strong> approved in combination with valsartan for CHF.&nbsp;</p>\n<p>Option D: <strong>Enoximone</strong> is a <strong>PDE-3 inhibitor.</strong></p><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2756",
      "difficulty": "medium"
    },
    {
      "text": "Sacubitril is a new drug approved for chronic heart failure. The mechanism of action of sacubitril is:",
      "choices": [
        {
          "id": 1,
          "text": "Angiotensin II inhibitor"
        },
        {
          "id": 2,
          "text": "ACE inhibitor"
        },
        {
          "id": 3,
          "text": "Renin inhibitor"
        },
        {
          "id": 4,
          "text": "Neutral endopeptidase inhibitor"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Sacubitril</strong> is a neutral endopeptidase <strong>(neprilysin) inhibitor.</strong></p>\n<p>Sacubitril is a prodrug that is activated to <strong>sacubitrilat.</strong> It can inhibit the enzyme neprilysin (neutral endopeptidase),&nbsp;which is responsible for the degradation of atrial and brain natriuretic peptides (reduction of blood volume). Therefore, it <strong>increases</strong> the levels of <strong>atrial and brain natriuretic peptides</strong> and <strong>lowers blood pressure.</strong></p>\n<div>In 2015, the FDA approved the use of sacubitril in <strong>combination</strong> with<strong> valsartan</strong>, at a ratio of <strong>1:1</strong>,&nbsp;for the treatment of chronic heart failure.</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3722",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not used in heart failure?",
      "choices": [
        {
          "id": 1,
          "text": "Trimetazidine"
        },
        {
          "id": 2,
          "text": "Sacubitril"
        },
        {
          "id": 3,
          "text": "Metoprolol"
        },
        {
          "id": 4,
          "text": "Nesiritide"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Trimetazidine</strong> is not used in heart failure.</p>\n<p>Trimetazidine is a newer antianginal drug that is a <strong>pFOX inhibitor</strong> which partially inhibits the fatty acid oxidation pathway in the myocardium. This <strong>decreases the oxygen requirement</strong> of the heart.</p>\n<p>Nesiritide (natriuretic peptide), sacubitril (neprilysin inhibitor) and metoprolol (beta-blocker) are used in the treatment of heart failure.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0132",
      "difficulty": "medium"
    }
  ]
}